Shopping Cart
Remove All
Your shopping cart is currently empty
Pinatuzumab vedotin is an antibody-drug conjugate (ADC) formed by conjugating the humanized anti-CD22 monoclonal antibody pinatuzumab with VcMMAE, and exhibits antitumor activity.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $413 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $987 | 2-4 weeks | 2-4 weeks | |
| 10 mg | Preferential | 2-4 weeks | 2-4 weeks |
| Description | Pinatuzumab vedotin is an antibody-drug conjugate (ADC) formed by conjugating the humanized anti-CD22 monoclonal antibody pinatuzumab with VcMMAE, and exhibits antitumor activity. |
| In vivo | Following the achievement of pseudo-equilibrium in mice after a single intravenous administration of Pinatuzumab vedotin at 5 mg/kg, the total systemic blood concentration of monomethyl auristatin E (MMAE) was approximately 5-fold higher than the plasma concentration. In rats, the ratio of total systemic MMAE blood concentration to plasma concentration was 1.65 [2]. |
| Synonyms | RG-7593, DCDT-2989S, DCDT2980S, anti-CD22-vc-MMAE |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal, ADC |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | MMAE |
| Gene ID | |
| Uniprot ID | |
| Target | Siglec-2/CD22 |
| Cas No. | 1313706-14-7 |
| Isotype | IgG1 |
| Storage | Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.